ArticleScientific reports2025
Epidemiological and transcriptome data identify potential key genes involved in inflammatory response for diabetic nephropathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The neutrophil percentage-to-albumin ratio (NPAR) is a novel inflammatory marker, and diabetic nephropathy (DN) are linked to inflammation. The primary objective of this investigation was to elucidate the functions and underlying mechanisms of inflammatory response in the development of DN. Epidemiological data from the National Health and Nutrition Examination Survey (NHANES) spanning 2009 to 2018 were utilized to systematically investigate the association between NPAR and DN. Furthermore, transcriptomic data from the Gene Expression Omnibus (GEO) were analyzed using bioinformatics approaches to examine potential functional mechanisms, focusing on gene expression and immune cell infiltration. A significant positive association was observed between NPAR and the risk of DN, as indicated by the multivariate linear regression analysis results [OR 1.62 (95% CI 1.22-2.15) and 2.06 (95% CI 1.53-2.77)]. Subgroup analyses and interaction testing indicated that factors such as age, gender, race, body mass index, smoking status, hypertension, and physical activity did not significantly modify this positive association (p for interaction > 0.05). Data from NHANES showed a non-linear relationship between NPAR and DN was observed, with a calculated inflection point of 1163.64 using a linear regression model. We identified 49 hub gene from transcriptomic data, with DUSP1, CXCR1, and SKIL as key genes in DN progression. The p38MAPK pathway plays a central role in DN development. Resveratrol strongly interacts with DUSP1, curcumin with CXCR1, and genistein with SKIL. The development and progression of DN is significantly influenced by the inflammatory response. NPAR serves as a reliable diagnostic indicator for DN, whereas resveratrol, curcumin, and genistein may have potential value in the treatment of DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.